A re-analysis of a clinical trial of GlaxoSmithKline's antidepressant Seroxat suggests the drug is ineffective and unsafe in younger patients, contradicting its earlier conclusions. The new study ...
This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...
In October, the MHRA reviewed data from the earliest trials of Seroxat. The information was supplied by GlaxoSmithKline in the late Eighties, and it was the MHRA's responsibility to analyse the ...
In the ongoing litigation over Apotex's generic version of GlaxoSmithKline's (GSK) antidepressant paroxetine hydrochloride (Paxil), the US Federal Circuit Appeals Court has reversed the previous ...
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
The FDA identified an estimated 9 excess GBS cases per million doses for Pfizer's Abrysvo and 7 excess cases per million for GSK's Arexvy. Updated warnings stem from Medicare-based studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback